GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tryptamine Therapeutics Ltd (ASX:TYP) » Definitions » Total Debt per Share

Tryptamine Therapeutics (ASX:TYP) Total Debt per Share : A$0.00 (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Tryptamine Therapeutics Total Debt per Share?

A$0.00 (As of Dec. 2023)

Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Tryptamine Therapeutics's Total Debt Per Share for the quarter that ended in Dec. 2023 was A$0.00.


Tryptamine Therapeutics Total Debt per Share Historical Data

The historical data trend for Tryptamine Therapeutics's Total Debt per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tryptamine Therapeutics Total Debt per Share Chart

Tryptamine Therapeutics Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Total Debt per Share
Get a 7-Day Free Trial - 0.02 0.02 0.05 0.01

Tryptamine Therapeutics Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Total Debt per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.02 0.05 0.02 0.01 -

Tryptamine Therapeutics Total Debt per Share Calculation

Tryptamine Therapeutics's Total Debt Per Share for the fiscal year that ended in Jun. 2023 is calculated as:

Tryptamine Therapeutics's Total Debt Per Share for the quarter that ended in Dec. 2023 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tryptamine Therapeutics Total Debt per Share Related Terms

Thank you for viewing the detailed overview of Tryptamine Therapeutics's Total Debt per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Tryptamine Therapeutics (ASX:TYP) Business Description

Traded in Other Exchanges
N/A
Address
697 Burke Road, Suite 201, Camberwell, VIC, AUS, 3124
Exopharm Ltd is a biopharmaceutical company that engages in the development of regenerative medicine in Australia. The company is engaged in developing and commercializing exosomes as therapeutic agents. The company operates in one segment namely the research and development of biopharmaceutical drugs. Revenue is generated from Australia.

Tryptamine Therapeutics (ASX:TYP) Headlines

No Headlines